Blackstone (BX) Eyes $2 Billion ZO Skin Health Exit

Blackstone Inc. (NYSE: BX ) is exploring a possible sale of ZO Skin Health, the medical-grade skincare company founded by dermatologist Dr. Zein Obagi. Reuters reported that the business could be valued at around $2 billion. The process is still in the early stages, and Blackstone is working with Citigroup and Raymond James on the potential sale. ZO sells products such as cleansers, serums, and exfoliators mainly through doctors and skincare professionals.

The timing could work in Blackstone Inc. (NYSE:BX)'s favor. There has been growing interest from strategic buyers in skincare brands that have a clinical angle and are sold through physicians. These businesses can have an edge over regular over-the-counter skincare because customers tend to put more trust in products recommended by dermatologists and other professionals.

Blackstone Could Cash in on Rising Skincare Demand

A sale at around $2 billion would give Blackstone Inc. (NYSE:BX) a meaningful opportunity to cash out of the investment and lock in the value it has created. It would also be a positive sign for the firm's consumer healthcare and beauty strategy. Getting a strong exit in a market where buyers are still being selective would show that Blackstone can find good businesses, grow them, and eventually sell them at attractive valuations.ZO also has something that many skincare brands do not. Its products are sold through physicians and skincare professionals, which gives the brand a more clinical and premium image. That can help the company charge higher prices and keep customers coming back. It also makes ZO more interesting to larger beauty and healthcare companies that want to add a dermatologist-backed brand to their portfolio.

For Blackstone, selling ZO would also free up capital for other investments. The firm could return some of that money to its investors or put it into businesses where it sees more growth potential. For an asset manager of Blackstone's size, being able to turn investments into cash is important because it helps support future fundraising and new deals.

The broader beauty market also shows that buyers are still prepared to spend heavily on brands they believe have strong growth potential. Reuters has pointed to deals such as L'Oréal's $4.7 billion purchase of Kering's beauty business and Henkel's $1.4 billion acquisition of Olaplex as examples.

So, the main bullish argument is that Blackstone Inc. (NYSE:BX) may have a good asset to sell at a time when strategic buyers are actively looking for premium, clinically positioned skincare brands. If multiple buyers come forward, Blackstone could have enough leverage to push the final price higher.